3-环丙基-3-氧代丙酸甲酯 、 N,N-二甲基甲酰胺二甲基缩醛 在
silica gel 、 正己烷 、 丙酮 作用下,
以
甲苯 为溶剂,
反应 3.0h,
以to give the title compound as a yellow oil (2.61 g)的产率得到2-环丙基羰基-3-二甲基氨基丙烯酸甲酯
[EN] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES<br/>[FR] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL-N-ARYL-BENZAMIDES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE CYTOKINES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
申请人:BOEHRINGER INGELHEIM PHARMA
公开号:WO2005090333A1
公开(公告)日:2005-09-29
Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
The present invention provides a compound represented by the following formula [1′] or a salt thereof:
wherein ring A, R
2
, R
3
, R
4
and X are as defined in the description, and an agent for the treatment or prophylaxis of a pathology involving glucocorticoid, or a 11βHSD1 inhibitor, containing the compound or a salt thereof.
The invention is concerned with novel pyrazol derivatives of formula (I),
wherein
R
1
, R
2
, R
3
, R
4
, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.
The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes.
wherein each symbol denotes as described in the specifications.
[EN] HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLE À UTILISER EN TANT QU'INHIBITEURS DE SÉPIAPTÉRINE RÉDUCTASE
申请人:QUARTET MEDICINE INC
公开号:WO2017059191A1
公开(公告)日:2017-04-06
Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.